ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.92% | -5.46% | 5,459.66% | 22,367.80% | 971,120.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.92% | -5.46% | 5,459.66% | 22,367.80% | 971,120.00% |
| Cost of Revenue | 107.44% | 63.47% | 39.02% | 15.95% | 2.76% |
| Gross Profit | -24.37% | -26.12% | 756.38% | 603.70% | 512.75% |
| SG&A Expenses | 149.21% | 221.06% | 378.22% | 288.09% | 142.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.69% | 185.94% | 270.29% | 199.95% | 100.28% |
| Operating Income | -647.81% | -5,720.56% | -50.04% | -4.59% | 56.34% |
| Income Before Tax | -1,189.26% | -2,168.28% | -62.41% | -6.44% | 69.09% |
| Income Tax Expenses | -127.78% | -127.78% | -- | -- | -- |
| Earnings from Continuing Operations | -1,165.02% | -2,241.76% | -63.00% | -7.08% | 68.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,165.02% | -2,241.76% | -63.00% | -7.08% | 68.51% |
| EBIT | -647.81% | -5,720.56% | -50.04% | -4.59% | 56.34% |
| EBITDA | -651.99% | -5,828.13% | -48.58% | -3.63% | 56.86% |
| EPS Basic | -1,152.69% | -2,282.66% | -59.03% | -4.44% | 69.26% |
| Normalized Basic EPS | -1,892.02% | -1,503.05% | -36.60% | 15.70% | 82.40% |
| EPS Diluted | -695.20% | -13,705.56% | -77.19% | -24.22% | 51.52% |
| Normalized Diluted EPS | -862.31% | -11,006.19% | -55.85% | -5.14% | 63.57% |
| Average Basic Shares Outstanding | 1.59% | 1.68% | 1.59% | 1.51% | 1.62% |
| Average Diluted Shares Outstanding | -3.80% | -3.74% | 7.24% | 7.18% | 7.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |